1. Home
  2. IRIX vs LIXT Comparison

IRIX vs LIXT Comparison

Compare IRIX & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IRIDEX Corporation

IRIX

IRIDEX Corporation

HOLD

Current Price

$1.51

Market Cap

24.2M

Sector

Health Care

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$3.21

Market Cap

25.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRIX
LIXT
Founded
1989
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.2M
25.4M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
IRIX
LIXT
Price
$1.51
$3.21
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
105.1K
79.7K
Earning Date
11-11-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,647,000.00
N/A
Revenue This Year
$9.61
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.58
N/A
52 Week Low
$0.78
$0.64
52 Week High
$1.72
$6.26

Technical Indicators

Market Signals
Indicator
IRIX
LIXT
Relative Strength Index (RSI) 70.64 39.95
Support Level $1.22 $3.26
Resistance Level $1.54 $3.66
Average True Range (ATR) 0.11 0.31
MACD 0.03 -0.04
Stochastic Oscillator 88.65 37.95

Price Performance

Historical Comparison
IRIX
LIXT

About IRIX IRIDEX Corporation

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: